Search Result
Results for "
Cy7 DiAcid
" in MedChemExpress (MCE) Product Catalog:
4
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-114118
-
|
|
GLP Receptor
Insulin Receptor
α-synuclein
Apoptosis
p38 MAPK
Autophagy
Bcl-2 Family
|
Neurological Disease
Metabolic Disease
Cancer
|
|
Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
|
-
-
- HY-P0014
-
-
-
- HY-P3506
-
|
LY3437943
|
GCGR
GLP Receptor
|
Metabolic Disease
|
|
Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity .
|
-
-
- HY-P3462
-
|
|
CGRP Receptor
|
Metabolic Disease
|
|
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .
|
-
-
- HY-P3462A
-
|
|
CGRP Receptor
|
Metabolic Disease
|
|
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .
|
-
-
- HY-P4146
-
|
BI 456906
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
|
-
-
- HY-114118B
-
|
|
GLP Receptor
Insulin Receptor
α-synuclein
Apoptosis
p38 MAPK
Autophagy
Bcl-2 Family
|
Neurological Disease
Metabolic Disease
Cancer
|
|
Semaglutide acetate is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
|
-
-
- HY-114118A
-
|
|
GLP Receptor
Insulin Receptor
α-synuclein
Apoptosis
p38 MAPK
Autophagy
Bcl-2 Family
|
Neurological Disease
Metabolic Disease
Cancer
|
|
Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
|
-
-
- HY-P3366
-
|
XW003
|
GCGR
|
Metabolic Disease
|
|
Ecnoglutide (XW003) is a long-acting, cAMP-biased glucagon-like peptide 1 (GLP-1) receptor agonist. Ecnoglutide can be used for research of T2DM and obesity .
|
-
-
- HY-P11274A
-
|
Amycretin sodium; NN 9487 sodium
|
Amylin Receptor
Insulin Receptor
GCGR
|
Metabolic Disease
|
Zenagamtide (Amycretin; NN 9487) sodium is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide sodium is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide sodium improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide sodium may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases .
|
-
-
- HY-114118CP
-
|
|
GLP Receptor
Insulin Receptor
α-synuclein
Apoptosis
p38 MAPK
Autophagy
Bcl-2 Family
|
Neurological Disease
Metabolic Disease
Cancer
|
|
Semaglutide (crude) is the crude form of Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances Autophagy, inhibits oxidative stress and Apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
|
-
-
- HY-P11245A
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
NN1213 acetate, a long-acting human amylin peptide analog, is a selective Amylin receptor agonist with EC50 values of 0.177 and 0.262 nM for hAMY3R and rAMY3R, respectively. NN1213 acetate significantly reduces food intake and fat mass. NN1213 acetate can reduce body weightin diet-induced obese rats. NN1213 acetate can be used for the research of obesity .
|
-
-
- HY-114118S3
-
|
|
Isotope-Labeled Compounds
GLP Receptor
Insulin Receptor
α-synuclein
Apoptosis
p38 MAPK
Autophagy
Bcl-2 Family
|
Metabolic Disease
|
|
Semaglutide- 13C6, 15N TFA is the 13C- and 15N-labeled Semaglutide TFA (HY-114118A). Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
|
-
-
- HY-P3506A
-
|
LY3437943 TFA
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity .
|
-
-
- HY-P2231
-
|
MEDI0382
|
GCGR
|
Metabolic Disease
|
|
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .
|
-
-
- HY-P2231A
-
|
MEDI0382 acetate
|
GCGR
|
Metabolic Disease
|
|
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .
|
-
-
- HY-P11274
-
|
Amycretin; NN 9487
|
Amylin Receptor
GCGR
Insulin Receptor
|
Metabolic Disease
|
Zenagamtide (Amycretin; NN 9487) is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases .
|
-
-
- HY-P10957
-
|
MBX 1416
|
GLP Receptor
|
Metabolic Disease
|
|
Imapextide is a glucagon-like peptide-1 (GLP-1) receptor antagonist that can be used in hypoglycemia research .
|
-
-
- HY-P3291
-
|
ZP7570
|
GCGR
|
Metabolic Disease
|
|
Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .
|
-
-
- HY-P10026
-
|
LY-3457263
|
Neuropeptide Y Receptor
|
Metabolic Disease
|
|
Nisotirotide (LY-3457263) is a subcutaneous injectable NPY2 receptor agonist. By mimicking peptide YY (PYY), Nisotirotide inhibits appetite and can be used in the research of diseases such as obesity and diabetes .
|
-
-
- HY-P11285A
-
|
Long acting GIPRA-1 TFA
|
Insulin Receptor
|
Metabolic Disease
|
|
LAGIPRA peptide TFA is a long-acting GIP1R agonist. LAGIPRA peptide TFA enhances insulin sensitivity by augmenting glucose disposal and reduces branched-chain amino acids (BCAAs) and ketoacids. LAGIPRA peptide TFA has the potential for the research of type 2 diabetes .
|
-
-
- HY-P11245
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
NN1213, a long-acting human amylin peptide analog, is a selective Amylin receptor agonist with EC50 values of 0.177 and 0.262 nM for hAMY3R and rAMY3R, respectively. NN1213 significantly reduces food intake and fat mass. NN1213 can reduce body weightin diet-induced obese rats. NN1213 can be used for the research of obesity .
|
-
-
- HY-P11271
-
-
-
- HY-P10302A
-
|
|
GLP Receptor
|
Metabolic Disease
Inflammation/Immunology
|
|
GLP-1R/GIPR agonist-1 sodium is a dual GLP-1/GIP receptor agonist, with an EC50 of 0.57 nM for GLP-1R and an EC50 of 0.75 nM for GIPR. GLP-1R/GIPR agonist-1 sodium reduces food intake, inhibits weight gain, repairs islet damage, improves glucose tolerance, regulates serum lipid and liver enzyme levels, ameliorates hepatic vacuolization, reduces hepatic fat accumulation, delays the progression of hepatic fibrosis, and exhibits long-lasting hypoglycemic activity. GLP-1R/GIPR agonist-1 sodium can be used in research related to type 2 diabetes, obesity, and non-alcoholic steatohepatitis .
|
-
-
- HY-D1095
-
|
|
Fluorescent Dye
|
|
|
Cy7 DiAcid belongs to the cyanine dye series and is a common fluorescent marker for biomolecules that can interact with biomolecules. Cyanine dyes may also bind to double-helical DNA through intercalation and exhibit enhanced fluorescence upon binding.
|
-
-
- HY-P10218
-
|
|
MARCKS
PKC
|
Inflammation/Immunology
Cancer
|
|
MANS peptide is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
|
-
-
- HY-P0014S1
-
|
|
Isotope-Labeled Compounds
GLP Receptor
GCGR
|
Others
|
|
Liraglutide- 13C6, 15 tetraTFA is the 13C and 15N labeled Liraglutide (HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .
|
-
-
- HY-P10271
-
|
NNC0090-2746; MAR709; RO6811135
|
GLP Receptor
|
Metabolic Disease
|
|
RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC50 of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .
|
-
-
- HY-P10218A
-
|
|
MARCKS
PKC
|
Inflammation/Immunology
Cancer
|
|
MANS peptide TFA is the TFA salt form of MANS peptide (HY-P10218). MANS peptide TFA is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
|
-
-
- HY-P0014B
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
Liraglutide (TFA) is an agonist of glucagon-like peptide 1 receptor (GLP-1). Liraglutide (TFA) can activate GLP-1, leading to the release of insulin in the presence of increased glucose concentration. Liraglutide (TFA) also reduces glucagon secretion in a glucose-dependent manner. Liraglutide (TFA) can be studied in research on type 2 diabetes .
|
-
-
- HY-P10269
-
|
GZR18
|
GLP Receptor
|
Metabolic Disease
|
|
Bofanglutide (GZR18) is an analog of glucagon-like peptide-1 (GLP-1), which exhibits agonistic activity for GLP-1 receptor, with an EC50 of 0.677 nM. GZR18 ameliorates type 2 diabetes .
|
-
-
- HY-P3143
-
|
|
PD-1/PD-L1
|
Cancer
|
|
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs .
|
-
-
- HY-P11285
-
|
Long acting GIPRA-1
|
Insulin Receptor
|
Metabolic Disease
|
|
LAGIPRA peptide is a long-acting GIP1R agonist. LAGIPRA peptide enhances insulin sensitivity by augmenting glucose disposal and reduces branched-chain amino acids (BCAAs) and ketoacids. LAGIPRA peptide has the potential for the research of type 2 diabetes .
|
-
-
- HY-P11273
-
-
-
- HY-153476A
-
|
|
GLP Receptor
GCGR
|
Inflammation/Immunology
|
|
GIP/GLP-1 dual receptor agonist-1 sodium is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 sodium is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .
|
-
-
- HY-153476
-
|
|
GCGR
GLP Receptor
|
Inflammation/Immunology
|
|
GIP/GLP-1 dual receptor agonist-1 is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .
|
-
-
- HY-P10032
-
-
-
- HY-P11290
-
-
-
- HY-P10341
-
|
|
GCGR
|
Metabolic Disease
|
|
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .
|
-
-
- HY-169089
-
|
|
Drug Derivative
|
Cancer
|
|
RP-182-PEG3-K palmitic acid-NH2 (Compound 1a) is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K palmitic acid-NH2 inhibits CD206 high M2-like macrophage (IC50 of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K palmitic acid-NH2 exhibits antitumor efficacy in mouse B16 melanoma allografts .
|
-
-
- HY-P3388
-
|
|
GLP Receptor
|
Cardiovascular Disease
Metabolic Disease
|
Utreglutide is an effective glucagon-like peptide 1 (GLP-1) receptor agonist. Utreglutide can lower blood pressure, blood lipids and body weight, and improve cardiovascular metabolism. Utreglutide can be used for research on type 2 diabetes or non-type 2 diabetes obesity .
|
-
-
- HY-P10591
-
|
Olatorepatidum
|
Insulin Receptor
GLP Receptor
|
Metabolic Disease
|
|
Olatorepatide (Olatorepatidum) is a dual gastric inhibitory polypeptide (GIP) receptor and glucagon like peptide 1 (GLP-1) receptor agonist, with antidiabetic effect .
|
-
-
- HY-P11271A
-
-
-
- HY-P3506B
-
|
LY3437943 acetate
|
GCGR
GLP Receptor
|
Metabolic Disease
|
|
Retatrutide (LY3437943) acetate is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide acetate can be used for the research of obesity .
|
-
-
- HY-P10965
-
|
ZT002
|
GLP Receptor
|
Metabolic Disease
|
|
Zovaglutide (ZT002) is a long-acting, selective GLP-1 receptor agonist. Zovaglutide enhances albumin binding capacity via dual fatty acid chain modification. Zovaglutide exerts metabolic effects through central and peripheral GLP-1 pathways, thereby promoting satiety, reducing caloric intake and enhancing glucose-dependent insulin secretion, with no activity against GIP or glucagon receptors. Zovaglutide can be used in research on type 2 diabetes or obesity .
|
-
-
- HY-P11233
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
Acmopatide (Compound E-153) is a dual-acting GIP/GLP-1 receptor agonist. Acmopatide is used in anti-diabetic research .
|
-
-
- HY-P11235
-
-
-
- HY-P0014AS
-
-
-
- HY-P4146A
-
|
BI 456906 TFA
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
|
-
-
- HY-P11270
-
|
BGM0504; BG128
|
Insulin Receptor
GLP Receptor
|
Metabolic Disease
|
|
Relsipatide (BG128) is a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Enicepatide can be studied in antidiabetic research .
|
-
- HY-P10302
-
|
|
GLP Receptor
Insulin Receptor
|
Metabolic Disease
|
|
GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .
|
-
- HY-P11237
-
|
CT-388
|
GCGR
Insulin Receptor
|
Metabolic Disease
|
|
Enicepatide is a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Enicepatide can be studied in antidiabetic research .
|
-
- HY-P11269
-
-
- HY-169089A
-
|
|
Drug Derivative
|
Cancer
|
|
RP-182-PEG3-K(palmitic acid)-NH2 (Compound 1a) TFA is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K(palmitic acid)-NH2 TFA inhibits CD206 high M2-like macrophage (IC50 of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K(palmitic acid)-NH2 TFA exhibits antitumor efficacy in mouse B16 melanoma allografts .
|
-
- HY-P10910
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
Vensemaglutide is the agonist for glucagon-like peptide 1 (GLP-1) receptor. Vensemaglutide can be used in research of diabetes or other metabolic disorders .
|
-
- HY-P0014A
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
Liraglutide acetate is the acetate form of Liraglutide (HY-P0014), a glucagon-like peptide-1 (GLP-1) receptor agonist studied in type 2 diabetes .
|
-
- HY-P10318
-
|
|
GLP Receptor
|
Endocrinology
|
|
SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .
|
-
- HY-P1614
-
-
- HY-P0041A
-
-
- HY-P0014S2
-
|
|
Isotope-Labeled Compounds
|
Others
|
|
Liraglutide- 13C6, 15 TFA is the 13C and 15N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .
|
-
- HY-P3143A
-
|
|
PD-1/PD-L1
|
Cancer
|
|
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .
|
-
- HY-P10951
-
|
(R)-PSMA I&T; (R)-PNT-2002
|
PSMA
|
Cancer
|
|
Zadavotide guraxetan (PSMA I&T; PNT-2002) is a prostate-specific membrane antigen (PSMA) inhibitor. Zadavotide guraxetan has antitumor activity and can be used in prostate cancer-targeted research .
|
-
- HY-P4146B
-
|
BI 456906 sodium
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
Survodutide (BI 456906) sodium is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide sodium, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide sodium has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
|
-
- HY-P11262
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
GUB021794 is a potent and highly selective glucagon-like peptide-1 receptor (GLP-1R) agonist developed using the streaMLine platform with an EC50 value of 18 pM. GUB021794 has a very weak activity against SCTR, with an EC50 value of 190 nM. GUB021794 can significantly reduce the body weight, food intake, and total fat mass of mice in a diet-induced obesity (DIO) model. GUB021794 can be used for research on obesity/diabetes .
|
-
- HY-113560
-
-
- HY-P1162
-
-
- HY-P11243
-
|
|
Ephrin Receptor
|
Neurological Disease
|
|
EphA4 agonist compound 23 is a novel EphA4 agonist peptide mimic. EphA4 agonist compound 23 exhibits high affinity, high selectivity, and significant receptor activation ability. EphA4 agonist compound 23 is commonly used in the study of neurodegenerative diseases .
|
-
- HY-P10876
-
|
|
Amyloid-β
|
Neurological Disease
|
|
mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .
|
-
- HY-P10869
-
dCNP
1 Publications Verification
|
Natriuretic Peptide Receptor (NPR)
|
Inflammation/Immunology
Cancer
|
|
dCNP binds to NPR-B/C receptor, activates cGMP signaling pathway, and regulates vascular function. dCNP exhibits anti-hypoxia property through downregulation of hypoxia-related genes expressions like HIF1α and HIF2α. dCNP inhibits the induction of tumor stroma and exhibits anti-fibrosis activity. dCNP upregulates CTLs, NK cells, and conventional type 1 dendritic cells in tumors, and activates immune responses .
|
-
- HY-P10200
-
|
|
Bacterial
|
Infection
|
|
CP7-FP13-2 is a peptide with antivirulence factor and antibacterial activity. CP7-FP13-2 inhibits the formation of Staphylococcus aureus biofilm and has good antibacterial efficacy in mice .
|
-
- HY-P10327
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
PP18 is a novel OXM-based dual GLP-1 and glucagon receptor agonist with EC50 values of 0.487 nM target hGLP-1R and 0.188 nM target hGcgR .
|
-
- HY-P0041
-
-
- HY-P5161
-
-
- HY-P5161A
-
-
- HY-109166
-
-
- HY-P11279
-
|
|
GLP Receptor
GCGR
Neuropeptide Y Receptor
|
Metabolic Disease
|
TC2 is an efficient GIPR-preferring monomeric quadruple agonist that can respectively activate GIPR, GLP-1R, GcgR, and Y2R with IC50 values of 0.47, 2.1, 30, and 55 nM respectively. TC2 exhibits a significant GLP-1R preference, with a significant reduction in β-inhibitory protein 2 (βArr2) recruitment, while maintaining a strong cAMP signal. TC2 can be used for research on obesity and diabetes .
|
-
- HY-P10881
-
-
- HY-P11275
-
|
|
GLP Receptor
GCGR
Neuropeptide Y Receptor
|
Metabolic Disease
|
TC4 is a highly balanced single-molecule quadruple agonist that can respectively activate GIPR, GLP-1R, GcgR, and Y2R with IC50 values of 0.95, 31, 81, and 1100 nM respectively. TC4 exhibits extremely strong signal bias on GLP-1R and has very low recruitment efficacy for β-inhibitor protein 2 (βArr2) and this strong cAMP preference is believed to maximize metabolic benefits (such as weight loss and hypoglycemia) while possibly minimizing side effects mediated by β-inhibitor protein recruitment (such as receptor desensitization). TC4 can be used for research on obesity and diabetes .
|
-
- HY-P10312
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
SPN009 (Sequence 3) is a GLP-1 Receptor agonist, with EC50 of 2.84 nM. SPN009 attenuates the type II diabetes in DB/DB mice models .
|
-
- HY-P10032A
-
-
- HY-P2595
-
|
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
SKF 103784 is an vasopressin antagonist with activity against vasopressin. SKF 103784 inhibits the physiological response caused by antidiuretic and is therefore used to study biological processes related to water and salt balance. SKF 103784 can also be used to explore pathological mechanisms related to cardiovascular diseases and endocrine dysfunction .
|
-
- HY-P11604
-
|
|
Phosphatase
|
Inflammation/Immunology
|
|
C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF is a cell-permeable and internalizable PTPN1/2 inhibitor, with IC50 values of 107.6 nM and 3375 nM, respectively. C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF restores insulin signaling in HepG2 cells. C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF achieves glycemic control in db/db diabetic mice. C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF can be used in the research of type 2 diabetes .
|
-
- HY-P11759
-
|
|
Drug Derivative
|
Cancer
|
|
Myr-transportan-Cys is a derivative of the cell-penetrating peptide Transportan (HY-P1732), and its conjugated myristoyl group (Myr) enhances the interaction between the peptide and cell membranes. Myr-transportan-Cys integrates three key delivery functions: nucleic acid condensation, cell penetration, and endosomal escape. Myr-transportan-Cys can form immunostimulatory tandem peptide nanocomplexes (iTPNCs) for encapsulating and delivering immunostimulatory oligonucleotide cargos to tumors .
|
-
- HY-N17580
-
|
|
Renin
|
Cardiovascular Disease
|
|
Lyciumin D acts as an angiotensin-converting enzyme inhibitor and renin inhibitor. Lyciumin D can be used for the research of hypertension .
|
-
- HY-P11670
-
-
- HY-P11235A
-
|
PF-08653944 acetate; MET-097 acetate
|
|
|
|
|
-
- HY-P11586
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
San45 is a nonselective dual amylin and calcitonin receptor agonist (DACRA) with nonselective potency relative to calcitonin receptor (CTR) and amylin 1 receptor (AMY₁R), and acts as a stabilizer of receptor-ligand complex and prolonged activator of cAMP signaling. San45 carries a conjugated lipid modification that can be used for the research of obesity .
|
-
- HY-P11665
-
-
- HY-P11811
-
-
- HY-114118C
-
|
|
GLP Receptor
Insulin Receptor
α-synuclein
Apoptosis
p38 MAPK
Autophagy
Bcl-2 Family
|
Neurological Disease
Metabolic Disease
Cancer
|
|
Semaglutide sodium is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide sodium promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide sodium also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide sodium has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide sodium can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
|
-
- HY-P11625
-
|
|
RXFP Receptor
|
Cardiovascular Disease
|
|
R9-13 is a fatty acid-conjugated relaxin and an agonist of LGR7 (RXFP1). R9-13 induces sustained pubic symphysis elongation in estrogen-pretreated mice. R9-13 exhibits long-acting pharmacokinetic profiles in rodents, with in vivo activity lasting up to one week after administration. R9-13 can be used in studies related to acute heart failure .
|
-
- HY-P11584
-
|
|
Amylin Receptor
CGRP Receptor
|
Metabolic Disease
|
|
KBP-066A is a long-acting dual amylin and calcitonin receptor agonist. KBP-066A can activate the CTR and AMY-R potently, with no off-target activity. KBP-066A reduces fasting blood glucose levels, fasting insulin levels, and body weight in diabetic rat models. KBP-066A can be used for the research of type 2 diabetes mellitus, obesity .
|
-
- HY-P11664
-
-
- HY-P11629
-
|
|
Amylin Receptor
CGRP Receptor
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
KBP-336 is a dual amylin and calcitonin receptor agonist (DACRA). KBP-336 exhibits antidiabetic and insulin-sensitizing properties, improves glucose levels, spatial learning, and memory in diabetic rats, and reduces blood glucose. KBP-336 also alleviates pain-like symptoms in osteoarthritis rats. KBP-336 also promotes weight and fat reduction. KBP-336 is useful for research on diabetes, obesity, and arthritis .
|
-
- HY-P11674
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
Zantrutide is a glucagon, gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Zantrutide can be used for the study of metabolic diseases .
|
-
- HY-114118F4
-
|
Semaglutide-Lys(FITC)
|
Fluorescent Dye
GLP Receptor
|
Metabolic Disease
|
|
Semaglutide-FITC (Semaglutide-Lys(FITC)) is a FITC-labeled Semaglutide (a GLP-1R agonist) (HY-114118). Semaglutide-FITC can be used to directly track the distribution, cellular uptake, and transmembrane transport process of vesicles through techniques such as fluorescence imaging and flow cytometry. Semaglutide-FITC can be employed to study the movement and penetration ability of mixed vesicles in porcine intestinal mucus in vitro .
|
-
- HY-P11830
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
UDA-6 is a potent calcitonin and amylin receptor agonist (DACRA). UDA-6 induces weight loss, improves metabolic and hepatic parameters, and stabilizes active receptor states in obesity rats. UDA-6 can be used for the research of obesity .
|
-
- HY-114118F5
-
-
- HY-P11675
-
-
- HY-P11667
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
Erzemdutide is a glucagon and glucagon-like peptide 1 (GLP-1) receptor agonist. Erzemdutide can be used for the study of obesity .
|
-
- HY-P10031A
-
|
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
SAR441255 TFA is a GLP-1R/GCGR/GIPR agonist, with human EC50 values of 1.03 pM, 1.01 pM, and 0.73 pM, respectively. SAR441255 TFA stimulates receptor activity and drives cAMP accumulation. SAR441255 TFA can be used for the research of type 2 diabetes, obesity .
|
-
- HY-P10031
-
|
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
SAR441255 is a GLP-1R/GCGR/GIPR agonist, with human EC50 values of 1.03 pM, 1.01 pM, and 0.73 pM, respectively. SAR441255 stimulates receptor activity and drives cAMP accumulation. SAR441255 can be used for the research of type 2 diabetes, obesity .
|
-
- HY-P10272
-
|
PTG-300
|
Ferroportin
|
Others
|
|
Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .
|
-
- HY-P11672
-
|
HDM1005
|
GLP Receptor
|
Metabolic Disease
|
|
Poterepatide (HDM1005) is a long-acting GLP-1R/GIPR peptide dual agonist. Poterepatide exhibits potent activity on both GLP-1 and GIP receptors. Poterepatide can be used for the study of obesity and type 2 diabetes .
|
-
- HY-P11666
-
|
LY-3537031
|
GLP Receptor
|
Metabolic Disease
|
|
Brenipatide (LY-3537031) is a dual glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptor agonist. Brenipatide can be used for the study of metabolic disorders, obesity and diabetes .
|
-
- HY-P10798A
-
|
LY-3841136 sodium
|
Amylin Receptor
Calcium Channel
|
Metabolic Disease
|
|
Eloralintide sodium is an Amylin Receptor agonist. Eloralintide sodium selectively activates AMY1R and AMY3R in cells expressing human or rat AMY1R, AMY3R or CTR. Eloralintide sodium activates AMYRs and CTR in rats, inducing a sustained decrease in plasma Ca 2+ levels. Eloralintide sodium reduces appetite and body weight in both lean and obese rats. Eloralintide sodium can be used for research related to obesity .
|
-
- HY-P10798
-
|
LY-3841136
|
Amylin Receptor
|
Metabolic Disease
|
|
Eloralintide is an amylin receptor (AMYR) activator and long-acting peptide. Eloralintide selectively activates amylin receptors. Eloralintide is modified with a C20 fatty diacid moiety that binds to amylin receptors while retaining selectivity from calcitonin receptors. Eloralintide induces decreased appetite.Eloralintide reduces body weight. Eloralintide can be used for the research of obesity .
|
-
- HY-P4070
-
|
|
Insulin Receptor
|
Metabolic Disease
|
|
Insulin icodec is an Insulin (HY-P0035) analog that strongly but reversibly binds to albumin. Insulin icodec has long plasma half-life. Insulin icodec modulates insulin receptor activity, controls blood glucose levels, reduces HbA1c levels, and binds reversibly to human serum albumin. Insulin icodec can be used for the research of type 2 diabetes mellitus .
|
-
- HY-172320
-
|
|
PD-1/PD-L1
|
Cancer
|
|
BMS-986238 is an orally active macrocyclic peptide PD-L1 inhibitor. BMS-986238 can be used in the research of tumors such as solid tumors and lymphomas .
|
-
- HY-P10964
-
|
|
GHSR
|
Endocrinology
|
|
Tezusomant is a growth hormone receptor antagonist. Tezusomant is promising for research on diseases caused by excessive growth hormone secretion, such as acromegaly .
|
-
- HY-P10563
-
|
BHV-1100
|
CD38
|
Cancer
|
|
Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recruit natural killer (NK) cells. Noraramtide enhances the ability of NK cells to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while avoiding mutual killing between NK cells. Noraramtide can be used for the study of autologous cancer immunity .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-D1095
-
|
|
Fluorescent Dyes
|
|
Cy7 DiAcid belongs to the cyanine dye series and is a common fluorescent marker for biomolecules that can interact with biomolecules. Cyanine dyes may also bind to double-helical DNA through intercalation and exhibit enhanced fluorescence upon binding.
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-114118
-
|
|
GLP Receptor
Insulin Receptor
α-synuclein
Apoptosis
p38 MAPK
Autophagy
Bcl-2 Family
|
Neurological Disease
Metabolic Disease
Cancer
|
|
Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
|
-
- HY-P0014
-
-
- HY-P3506
-
|
LY3437943
|
GCGR
GLP Receptor
|
Metabolic Disease
|
|
Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity .
|
-
- HY-P3462
-
|
|
CGRP Receptor
|
Metabolic Disease
|
|
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .
|
-
- HY-P3462A
-
|
|
CGRP Receptor
|
Metabolic Disease
|
|
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .
|
-
- HY-P4146
-
|
BI 456906
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
|
-
- HY-114118B
-
|
|
GLP Receptor
Insulin Receptor
α-synuclein
Apoptosis
p38 MAPK
Autophagy
Bcl-2 Family
|
Neurological Disease
Metabolic Disease
Cancer
|
|
Semaglutide acetate is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
|
-
- HY-114118A
-
|
|
GLP Receptor
Insulin Receptor
α-synuclein
Apoptosis
p38 MAPK
Autophagy
Bcl-2 Family
|
Neurological Disease
Metabolic Disease
Cancer
|
|
Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
|
-
- HY-P3366
-
|
XW003
|
GCGR
|
Metabolic Disease
|
|
Ecnoglutide (XW003) is a long-acting, cAMP-biased glucagon-like peptide 1 (GLP-1) receptor agonist. Ecnoglutide can be used for research of T2DM and obesity .
|
-
- HY-P11274A
-
|
Amycretin sodium; NN 9487 sodium
|
Amylin Receptor
Insulin Receptor
GCGR
|
Metabolic Disease
|
Zenagamtide (Amycretin; NN 9487) sodium is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide sodium is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide sodium improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide sodium may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases .
|
-
- HY-114118CP
-
|
|
GLP Receptor
Insulin Receptor
α-synuclein
Apoptosis
p38 MAPK
Autophagy
Bcl-2 Family
|
Neurological Disease
Metabolic Disease
Cancer
|
|
Semaglutide (crude) is the crude form of Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances Autophagy, inhibits oxidative stress and Apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
|
-
- HY-P11245A
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
NN1213 acetate, a long-acting human amylin peptide analog, is a selective Amylin receptor agonist with EC50 values of 0.177 and 0.262 nM for hAMY3R and rAMY3R, respectively. NN1213 acetate significantly reduces food intake and fat mass. NN1213 acetate can reduce body weightin diet-induced obese rats. NN1213 acetate can be used for the research of obesity .
|
-
- HY-P3506A
-
|
LY3437943 TFA
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity .
|
-
- HY-P2231
-
|
MEDI0382
|
GCGR
|
Metabolic Disease
|
|
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .
|
-
- HY-P2231A
-
|
MEDI0382 acetate
|
GCGR
|
Metabolic Disease
|
|
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .
|
-
- HY-P11274
-
|
Amycretin; NN 9487
|
Amylin Receptor
GCGR
Insulin Receptor
|
Metabolic Disease
|
Zenagamtide (Amycretin; NN 9487) is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases .
|
-
- HY-P10957
-
|
MBX 1416
|
GLP Receptor
|
Metabolic Disease
|
|
Imapextide is a glucagon-like peptide-1 (GLP-1) receptor antagonist that can be used in hypoglycemia research .
|
-
- HY-P3291
-
|
ZP7570
|
GCGR
|
Metabolic Disease
|
|
Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .
|
-
- HY-P10026
-
|
LY-3457263
|
Neuropeptide Y Receptor
|
Metabolic Disease
|
|
Nisotirotide (LY-3457263) is a subcutaneous injectable NPY2 receptor agonist. By mimicking peptide YY (PYY), Nisotirotide inhibits appetite and can be used in the research of diseases such as obesity and diabetes .
|
-
- HY-P11285A
-
|
Long acting GIPRA-1 TFA
|
Insulin Receptor
|
Metabolic Disease
|
|
LAGIPRA peptide TFA is a long-acting GIP1R agonist. LAGIPRA peptide TFA enhances insulin sensitivity by augmenting glucose disposal and reduces branched-chain amino acids (BCAAs) and ketoacids. LAGIPRA peptide TFA has the potential for the research of type 2 diabetes .
|
-
- HY-P11245
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
NN1213, a long-acting human amylin peptide analog, is a selective Amylin receptor agonist with EC50 values of 0.177 and 0.262 nM for hAMY3R and rAMY3R, respectively. NN1213 significantly reduces food intake and fat mass. NN1213 can reduce body weightin diet-induced obese rats. NN1213 can be used for the research of obesity .
|
-
- HY-P11271
-
-
- HY-P10302A
-
|
|
GLP Receptor
|
Metabolic Disease
Inflammation/Immunology
|
|
GLP-1R/GIPR agonist-1 sodium is a dual GLP-1/GIP receptor agonist, with an EC50 of 0.57 nM for GLP-1R and an EC50 of 0.75 nM for GIPR. GLP-1R/GIPR agonist-1 sodium reduces food intake, inhibits weight gain, repairs islet damage, improves glucose tolerance, regulates serum lipid and liver enzyme levels, ameliorates hepatic vacuolization, reduces hepatic fat accumulation, delays the progression of hepatic fibrosis, and exhibits long-lasting hypoglycemic activity. GLP-1R/GIPR agonist-1 sodium can be used in research related to type 2 diabetes, obesity, and non-alcoholic steatohepatitis .
|
-
- HY-P10218
-
|
|
MARCKS
PKC
|
Inflammation/Immunology
Cancer
|
|
MANS peptide is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
|
-
- HY-P0014S1
-
|
|
Isotope-Labeled Compounds
GLP Receptor
GCGR
|
Others
|
|
Liraglutide- 13C6, 15 tetraTFA is the 13C and 15N labeled Liraglutide (HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .
|
-
- HY-P10271
-
|
NNC0090-2746; MAR709; RO6811135
|
GLP Receptor
|
Metabolic Disease
|
|
RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC50 of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .
|
-
- HY-P10218A
-
|
|
MARCKS
PKC
|
Inflammation/Immunology
Cancer
|
|
MANS peptide TFA is the TFA salt form of MANS peptide (HY-P10218). MANS peptide TFA is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
|
-
- HY-P0014B
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
Liraglutide (TFA) is an agonist of glucagon-like peptide 1 receptor (GLP-1). Liraglutide (TFA) can activate GLP-1, leading to the release of insulin in the presence of increased glucose concentration. Liraglutide (TFA) also reduces glucagon secretion in a glucose-dependent manner. Liraglutide (TFA) can be studied in research on type 2 diabetes .
|
-
- HY-P10269
-
|
GZR18
|
GLP Receptor
|
Metabolic Disease
|
|
Bofanglutide (GZR18) is an analog of glucagon-like peptide-1 (GLP-1), which exhibits agonistic activity for GLP-1 receptor, with an EC50 of 0.677 nM. GZR18 ameliorates type 2 diabetes .
|
-
- HY-P3143
-
|
|
PD-1/PD-L1
|
Cancer
|
|
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs .
|
-
- HY-P11285
-
|
Long acting GIPRA-1
|
Insulin Receptor
|
Metabolic Disease
|
|
LAGIPRA peptide is a long-acting GIP1R agonist. LAGIPRA peptide enhances insulin sensitivity by augmenting glucose disposal and reduces branched-chain amino acids (BCAAs) and ketoacids. LAGIPRA peptide has the potential for the research of type 2 diabetes .
|
-
- HY-P11273
-
-
- HY-153476A
-
|
|
GLP Receptor
GCGR
|
Inflammation/Immunology
|
|
GIP/GLP-1 dual receptor agonist-1 sodium is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 sodium is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .
|
-
- HY-153476
-
|
|
GCGR
GLP Receptor
|
Inflammation/Immunology
|
|
GIP/GLP-1 dual receptor agonist-1 is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .
|
-
- HY-P10032
-
-
- HY-P11290
-
-
- HY-P10341
-
|
|
GCGR
|
Metabolic Disease
|
|
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .
|
-
- HY-169089
-
|
|
Drug Derivative
|
Cancer
|
|
RP-182-PEG3-K palmitic acid-NH2 (Compound 1a) is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K palmitic acid-NH2 inhibits CD206 high M2-like macrophage (IC50 of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K palmitic acid-NH2 exhibits antitumor efficacy in mouse B16 melanoma allografts .
|
-
- HY-P3388
-
|
|
GLP Receptor
|
Cardiovascular Disease
Metabolic Disease
|
Utreglutide is an effective glucagon-like peptide 1 (GLP-1) receptor agonist. Utreglutide can lower blood pressure, blood lipids and body weight, and improve cardiovascular metabolism. Utreglutide can be used for research on type 2 diabetes or non-type 2 diabetes obesity .
|
-
- HY-P10591
-
|
Olatorepatidum
|
Insulin Receptor
GLP Receptor
|
Metabolic Disease
|
|
Olatorepatide (Olatorepatidum) is a dual gastric inhibitory polypeptide (GIP) receptor and glucagon like peptide 1 (GLP-1) receptor agonist, with antidiabetic effect .
|
-
- HY-P11271A
-
-
- HY-P3506B
-
|
LY3437943 acetate
|
GCGR
GLP Receptor
|
Metabolic Disease
|
|
Retatrutide (LY3437943) acetate is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide acetate can be used for the research of obesity .
|
-
- HY-P10965
-
|
ZT002
|
GLP Receptor
|
Metabolic Disease
|
|
Zovaglutide (ZT002) is a long-acting, selective GLP-1 receptor agonist. Zovaglutide enhances albumin binding capacity via dual fatty acid chain modification. Zovaglutide exerts metabolic effects through central and peripheral GLP-1 pathways, thereby promoting satiety, reducing caloric intake and enhancing glucose-dependent insulin secretion, with no activity against GIP or glucagon receptors. Zovaglutide can be used in research on type 2 diabetes or obesity .
|
-
- HY-P11233
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
Acmopatide (Compound E-153) is a dual-acting GIP/GLP-1 receptor agonist. Acmopatide is used in anti-diabetic research .
|
-
- HY-P11235
-
-
- HY-P0014AS
-
-
- HY-P4146A
-
|
BI 456906 TFA
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
|
-
- HY-P11270
-
|
BGM0504; BG128
|
Insulin Receptor
GLP Receptor
|
Metabolic Disease
|
|
Relsipatide (BG128) is a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Enicepatide can be studied in antidiabetic research .
|
-
- HY-P10302
-
|
|
GLP Receptor
Insulin Receptor
|
Metabolic Disease
|
|
GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .
|
-
- HY-P11237
-
|
CT-388
|
GCGR
Insulin Receptor
|
Metabolic Disease
|
|
Enicepatide is a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Enicepatide can be studied in antidiabetic research .
|
- HY-P11269
-
- HY-169089A
-
|
|
Drug Derivative
|
Cancer
|
|
RP-182-PEG3-K(palmitic acid)-NH2 (Compound 1a) TFA is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K(palmitic acid)-NH2 TFA inhibits CD206 high M2-like macrophage (IC50 of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K(palmitic acid)-NH2 TFA exhibits antitumor efficacy in mouse B16 melanoma allografts .
|
- HY-P10910
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
Vensemaglutide is the agonist for glucagon-like peptide 1 (GLP-1) receptor. Vensemaglutide can be used in research of diabetes or other metabolic disorders .
|
- HY-P0014A
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
Liraglutide acetate is the acetate form of Liraglutide (HY-P0014), a glucagon-like peptide-1 (GLP-1) receptor agonist studied in type 2 diabetes .
|
- HY-P10318
-
|
|
GLP Receptor
|
Endocrinology
|
|
SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .
|
- HY-P1614
-
- HY-P0041A
-
- HY-P0014S2
-
|
|
Isotope-Labeled Compounds
|
Others
|
|
Liraglutide- 13C6, 15 TFA is the 13C and 15N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .
|
- HY-P3143A
-
|
|
PD-1/PD-L1
|
Cancer
|
|
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .
|
- HY-P10951
-
|
(R)-PSMA I&T; (R)-PNT-2002
|
PSMA
|
Cancer
|
|
Zadavotide guraxetan (PSMA I&T; PNT-2002) is a prostate-specific membrane antigen (PSMA) inhibitor. Zadavotide guraxetan has antitumor activity and can be used in prostate cancer-targeted research .
|
- HY-P4146B
-
|
BI 456906 sodium
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
Survodutide (BI 456906) sodium is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide sodium, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide sodium has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
|
- HY-P11262
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
GUB021794 is a potent and highly selective glucagon-like peptide-1 receptor (GLP-1R) agonist developed using the streaMLine platform with an EC50 value of 18 pM. GUB021794 has a very weak activity against SCTR, with an EC50 value of 190 nM. GUB021794 can significantly reduce the body weight, food intake, and total fat mass of mice in a diet-induced obesity (DIO) model. GUB021794 can be used for research on obesity/diabetes .
|
- HY-113560
-
- HY-P1162
-
- HY-P11243
-
|
|
Ephrin Receptor
|
Neurological Disease
|
|
EphA4 agonist compound 23 is a novel EphA4 agonist peptide mimic. EphA4 agonist compound 23 exhibits high affinity, high selectivity, and significant receptor activation ability. EphA4 agonist compound 23 is commonly used in the study of neurodegenerative diseases .
|
- HY-P10876
-
|
|
Amyloid-β
|
Neurological Disease
|
|
mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .
|
- HY-P10869
-
dCNP
1 Publications Verification
|
Natriuretic Peptide Receptor (NPR)
|
Inflammation/Immunology
Cancer
|
|
dCNP binds to NPR-B/C receptor, activates cGMP signaling pathway, and regulates vascular function. dCNP exhibits anti-hypoxia property through downregulation of hypoxia-related genes expressions like HIF1α and HIF2α. dCNP inhibits the induction of tumor stroma and exhibits anti-fibrosis activity. dCNP upregulates CTLs, NK cells, and conventional type 1 dendritic cells in tumors, and activates immune responses .
|
- HY-P4837
-
|
|
Peptides
|
Others
|
|
Ac-Lys-D-Ala-D-lactic acid is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .
|
- HY-P10200
-
|
|
Bacterial
|
Infection
|
|
CP7-FP13-2 is a peptide with antivirulence factor and antibacterial activity. CP7-FP13-2 inhibits the formation of Staphylococcus aureus biofilm and has good antibacterial efficacy in mice .
|
- HY-P10327
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
PP18 is a novel OXM-based dual GLP-1 and glucagon receptor agonist with EC50 values of 0.487 nM target hGLP-1R and 0.188 nM target hGcgR .
|
- HY-P0041
-
- HY-P5161
-
- HY-P5161A
-
- HY-109166
-
- HY-P11279
-
|
|
GLP Receptor
GCGR
Neuropeptide Y Receptor
|
Metabolic Disease
|
TC2 is an efficient GIPR-preferring monomeric quadruple agonist that can respectively activate GIPR, GLP-1R, GcgR, and Y2R with IC50 values of 0.47, 2.1, 30, and 55 nM respectively. TC2 exhibits a significant GLP-1R preference, with a significant reduction in β-inhibitory protein 2 (βArr2) recruitment, while maintaining a strong cAMP signal. TC2 can be used for research on obesity and diabetes .
|
- HY-P10881
-
- HY-P11275
-
|
|
GLP Receptor
GCGR
Neuropeptide Y Receptor
|
Metabolic Disease
|
TC4 is a highly balanced single-molecule quadruple agonist that can respectively activate GIPR, GLP-1R, GcgR, and Y2R with IC50 values of 0.95, 31, 81, and 1100 nM respectively. TC4 exhibits extremely strong signal bias on GLP-1R and has very low recruitment efficacy for β-inhibitor protein 2 (βArr2) and this strong cAMP preference is believed to maximize metabolic benefits (such as weight loss and hypoglycemia) while possibly minimizing side effects mediated by β-inhibitor protein recruitment (such as receptor desensitization). TC4 can be used for research on obesity and diabetes .
|
- HY-P10312
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
SPN009 (Sequence 3) is a GLP-1 Receptor agonist, with EC50 of 2.84 nM. SPN009 attenuates the type II diabetes in DB/DB mice models .
|
- HY-P10381
-
|
|
Peptides
|
Others
|
|
palm11-TTDS-PrRP31 is a strong agonist of GPR10 (EC50: 84 pM). palm11-TTDS-PrRP31 has long-lasting anorexigenic effects .
|
- HY-P10032A
-
- HY-P2595
-
|
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
SKF 103784 is an vasopressin antagonist with activity against vasopressin. SKF 103784 inhibits the physiological response caused by antidiuretic and is therefore used to study biological processes related to water and salt balance. SKF 103784 can also be used to explore pathological mechanisms related to cardiovascular diseases and endocrine dysfunction .
|
- HY-P11604
-
|
|
Phosphatase
|
Inflammation/Immunology
|
|
C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF is a cell-permeable and internalizable PTPN1/2 inhibitor, with IC50 values of 107.6 nM and 3375 nM, respectively. C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF restores insulin signaling in HepG2 cells. C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF achieves glycemic control in db/db diabetic mice. C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF can be used in the research of type 2 diabetes .
|
- HY-P11759
-
|
|
Drug Derivative
|
Cancer
|
|
Myr-transportan-Cys is a derivative of the cell-penetrating peptide Transportan (HY-P1732), and its conjugated myristoyl group (Myr) enhances the interaction between the peptide and cell membranes. Myr-transportan-Cys integrates three key delivery functions: nucleic acid condensation, cell penetration, and endosomal escape. Myr-transportan-Cys can form immunostimulatory tandem peptide nanocomplexes (iTPNCs) for encapsulating and delivering immunostimulatory oligonucleotide cargos to tumors .
|
- HY-N17580
-
|
|
Renin
|
Cardiovascular Disease
|
|
Lyciumin D acts as an angiotensin-converting enzyme inhibitor and renin inhibitor. Lyciumin D can be used for the research of hypertension .
|
- HY-P11670
-
- HY-P11235A
-
|
PF-08653944 acetate; MET-097 acetate
|
|
|
|
|
- HY-P11586
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
San45 is a nonselective dual amylin and calcitonin receptor agonist (DACRA) with nonselective potency relative to calcitonin receptor (CTR) and amylin 1 receptor (AMY₁R), and acts as a stabilizer of receptor-ligand complex and prolonged activator of cAMP signaling. San45 carries a conjugated lipid modification that can be used for the research of obesity .
|
- HY-P11665
-
- HY-P11811
-
- HY-114118C
-
|
|
GLP Receptor
Insulin Receptor
α-synuclein
Apoptosis
p38 MAPK
Autophagy
Bcl-2 Family
|
Neurological Disease
Metabolic Disease
Cancer
|
|
Semaglutide sodium is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide sodium promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide sodium also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide sodium has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide sodium can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
|
- HY-P11625
-
|
|
RXFP Receptor
|
Cardiovascular Disease
|
|
R9-13 is a fatty acid-conjugated relaxin and an agonist of LGR7 (RXFP1). R9-13 induces sustained pubic symphysis elongation in estrogen-pretreated mice. R9-13 exhibits long-acting pharmacokinetic profiles in rodents, with in vivo activity lasting up to one week after administration. R9-13 can be used in studies related to acute heart failure .
|
- HY-P11584
-
|
|
Amylin Receptor
CGRP Receptor
|
Metabolic Disease
|
|
KBP-066A is a long-acting dual amylin and calcitonin receptor agonist. KBP-066A can activate the CTR and AMY-R potently, with no off-target activity. KBP-066A reduces fasting blood glucose levels, fasting insulin levels, and body weight in diabetic rat models. KBP-066A can be used for the research of type 2 diabetes mellitus, obesity .
|
- HY-P11664
-
- HY-P11629
-
|
|
Amylin Receptor
CGRP Receptor
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
KBP-336 is a dual amylin and calcitonin receptor agonist (DACRA). KBP-336 exhibits antidiabetic and insulin-sensitizing properties, improves glucose levels, spatial learning, and memory in diabetic rats, and reduces blood glucose. KBP-336 also alleviates pain-like symptoms in osteoarthritis rats. KBP-336 also promotes weight and fat reduction. KBP-336 is useful for research on diabetes, obesity, and arthritis .
|
- HY-P11674
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
Zantrutide is a glucagon, gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Zantrutide can be used for the study of metabolic diseases .
|
- HY-114118F4
-
|
Semaglutide-Lys(FITC)
|
Fluorescent Dye
GLP Receptor
|
Metabolic Disease
|
|
Semaglutide-FITC (Semaglutide-Lys(FITC)) is a FITC-labeled Semaglutide (a GLP-1R agonist) (HY-114118). Semaglutide-FITC can be used to directly track the distribution, cellular uptake, and transmembrane transport process of vesicles through techniques such as fluorescence imaging and flow cytometry. Semaglutide-FITC can be employed to study the movement and penetration ability of mixed vesicles in porcine intestinal mucus in vitro .
|
- HY-P11830
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
UDA-6 is a potent calcitonin and amylin receptor agonist (DACRA). UDA-6 induces weight loss, improves metabolic and hepatic parameters, and stabilizes active receptor states in obesity rats. UDA-6 can be used for the research of obesity .
|
- HY-114118F5
-
- HY-P11675
-
- HY-P11667
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
Erzemdutide is a glucagon and glucagon-like peptide 1 (GLP-1) receptor agonist. Erzemdutide can be used for the study of obesity .
|
- HY-P10031A
-
|
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
SAR441255 TFA is a GLP-1R/GCGR/GIPR agonist, with human EC50 values of 1.03 pM, 1.01 pM, and 0.73 pM, respectively. SAR441255 TFA stimulates receptor activity and drives cAMP accumulation. SAR441255 TFA can be used for the research of type 2 diabetes, obesity .
|
- HY-P10031
-
|
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
SAR441255 is a GLP-1R/GCGR/GIPR agonist, with human EC50 values of 1.03 pM, 1.01 pM, and 0.73 pM, respectively. SAR441255 stimulates receptor activity and drives cAMP accumulation. SAR441255 can be used for the research of type 2 diabetes, obesity .
|
- HY-P10272
-
|
PTG-300
|
Ferroportin
|
Others
|
|
Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .
|
- HY-P11672
-
|
HDM1005
|
GLP Receptor
|
Metabolic Disease
|
|
Poterepatide (HDM1005) is a long-acting GLP-1R/GIPR peptide dual agonist. Poterepatide exhibits potent activity on both GLP-1 and GIP receptors. Poterepatide can be used for the study of obesity and type 2 diabetes .
|
- HY-P11666
-
|
LY-3537031
|
GLP Receptor
|
Metabolic Disease
|
|
Brenipatide (LY-3537031) is a dual glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptor agonist. Brenipatide can be used for the study of metabolic disorders, obesity and diabetes .
|
- HY-P10798A
-
|
LY-3841136 sodium
|
Amylin Receptor
Calcium Channel
|
Metabolic Disease
|
|
Eloralintide sodium is an Amylin Receptor agonist. Eloralintide sodium selectively activates AMY1R and AMY3R in cells expressing human or rat AMY1R, AMY3R or CTR. Eloralintide sodium activates AMYRs and CTR in rats, inducing a sustained decrease in plasma Ca 2+ levels. Eloralintide sodium reduces appetite and body weight in both lean and obese rats. Eloralintide sodium can be used for research related to obesity .
|
- HY-P10798
-
|
LY-3841136
|
Amylin Receptor
|
Metabolic Disease
|
|
Eloralintide is an amylin receptor (AMYR) activator and long-acting peptide. Eloralintide selectively activates amylin receptors. Eloralintide is modified with a C20 fatty diacid moiety that binds to amylin receptors while retaining selectivity from calcitonin receptors. Eloralintide induces decreased appetite.Eloralintide reduces body weight. Eloralintide can be used for the research of obesity .
|
- HY-P4070
-
|
|
Insulin Receptor
|
Metabolic Disease
|
|
Insulin icodec is an Insulin (HY-P0035) analog that strongly but reversibly binds to albumin. Insulin icodec has long plasma half-life. Insulin icodec modulates insulin receptor activity, controls blood glucose levels, reduces HbA1c levels, and binds reversibly to human serum albumin. Insulin icodec can be used for the research of type 2 diabetes mellitus .
|
- HY-172320
-
|
|
PD-1/PD-L1
|
Cancer
|
|
BMS-986238 is an orally active macrocyclic peptide PD-L1 inhibitor. BMS-986238 can be used in the research of tumors such as solid tumors and lymphomas .
|
- HY-P10964
-
|
|
GHSR
|
Endocrinology
|
|
Tezusomant is a growth hormone receptor antagonist. Tezusomant is promising for research on diseases caused by excessive growth hormone secretion, such as acromegaly .
|
- HY-P10563
-
|
BHV-1100
|
CD38
|
Cancer
|
|
Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recruit natural killer (NK) cells. Noraramtide enhances the ability of NK cells to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while avoiding mutual killing between NK cells. Noraramtide can be used for the study of autologous cancer immunity .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-114118S3
-
|
|
|
Semaglutide- 13C6, 15N TFA is the 13C- and 15N-labeled Semaglutide TFA (HY-114118A). Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
|
-
-
- HY-P0014S1
-
|
|
|
Liraglutide- 13C6, 15 tetraTFA is the 13C and 15N labeled Liraglutide (HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .
|
-
-
- HY-P0014AS
-
|
|
|
Liraglutide-d8 tetraTFA is deuterium labeled Liraglutide (HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .
|
-
-
- HY-P0014S2
-
|
|
|
Liraglutide- 13C6, 15 TFA is the 13C and 15N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
